Sarcoma, Soft Tissue Clinical Trial
Official title:
Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma
Wound complications after sarcoma resection are frequent and potentially devastating problem. The burden of surgical wound complications in the lower extremity after preoperative external beam radiation therapy (EBRT) for soft tissue sarcoma is estimated at 43%. A noninvasive method of predicting complications would be extremely beneficial. The aim of this study is to evaluate the relationship between preoperative skin oxygenation and wound outcomes in a multi-center prospective analysis. This information could lead to a change in practice regarding surgical timing and adjunctive interventions to improve wound healing outcomes.
It is estimated that there are 11,400 new cases of soft tissue sarcoma diagnosed in the United States annually. Most high-grade sarcomas, and other selected low or intermediate grade sarcomas, are treated with a limb salvage surgical resection in conjunction with external beam radiation to optimize local control. The current preference of most practicing orthopaedic/surgical oncologists and radiation oncologists is to implement the radiation treatments prior to surgery to diminish the total radiation dose and field size, thereby optimizing long-term functional results of the salvaged limb. While there are clear advantages of preoperative radiation, there are well-demonstrated negative consequences with regard to healing of the surgical wound. Currently there are no reliable clinical criteria to aid physicians in determining an individual patient's risk of developing a postoperative wound complication. This fact, combined with the rarity of the sarcoma diagnosis, has prevented improvement in wound outcomes in sarcoma patients. This project is designed to close this critical gap in knowledge. The investigators propose utilizing a preoperative measurement of transcutaneous oxygen (Tc02) at the proposed incision to classify patients into high- and low-risk categories for development of wound complications after resection. Measurement of preoperative TcO2 represents a novel application of a simple, noninvasive method by which to assess skin oxygenation. Given the results of an already completed pilot investigation (Nystrom 2016), the investigators believe that this important clinical problem is well suited for a prospective, multi-disciplinary, multi-institutional investigation. A successful project would result in an enhanced ability to identify wounds at risk prior to surgery and allow for additional investigation into perioperative interventions (delay of surgery until recovery of oxygenation, increasing suture duration, judicious use of muscle flaps and skin grafts, postoperative hyperbaric oxygen, or treatment with incisional wound vacuum-assisted closure) that may mitigate this significant adverse outcome. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03985722 -
Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
|
Phase 1 | |
Withdrawn |
NCT02464332 -
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
|
Phase 1 | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Completed |
NCT00289809 -
TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01185964 -
A Study of IMC-3G3 in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00753688 -
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
|
Phase 3 | |
Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT03798795 -
Radiomics for Tumor Grading of Soft Tissue Sarcomas.
|
||
Terminated |
NCT02929394 -
Trabectedin Maintenance Post 1st-line in STS
|
Phase 3 | |
Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00406601 -
BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT00297258 -
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT06114173 -
Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma
|
Early Phase 1 | |
Completed |
NCT00061659 -
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT03815474 -
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
|
Phase 2 | |
Recruiting |
NCT02812654 -
Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment
|
Phase 2 | |
Completed |
NCT00204620 -
Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
|
Phase 2 | |
Completed |
NCT03058406 -
A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
|
||
Active, not recruiting |
NCT02415816 -
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
|
N/A |